Statin Use Decreases Cancer-Related Mortality Risk, Study Finds

A recent study has found that use of statins considerably decreases cancer-related mortality among patients with non-alcoholic fatty liver disease (NAFLD).

Photo: Statin Medication | InStyleHealth


Research analysis involved 10,821 NAFLD patients who participated in eight rounds of the National Health and Nutrition Examination Survey (NHANES). Mortality data were gathered by connecting the NHANES data to National Death Index.


There were 2,523 participants who were statin users (23 percent). The Multivariable Cox proportional hazards analysis showed that compared with non-users of statins, users had a 43 percent lower risk of cancer mortality.


Conversely, shorter duration of statin use failed to confer a benefit. Particularly, less than 1 year of statin use revealed no significant effect on cancer mortality, whereas use for 1 to 5 years cut the results by 35 percent and for those greater than 5 years it cuts the outcome by 56 percent.


Survival rate was apparent in NAFLD patients at either low or high risk of liver fibrosis.

Provided that statin indications are predominant among NAFLD patients, the current data may help clinical decision making, as many patients do not receive benefit in the event that the statin is discontinued due to liver test abnormalities. For complete details of the study, click here.



Source: Clin Gastroenterol Hepatol 2021;doi:10.1097/MCG.0000000000001503

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post